Immune Thrombocytopenia, ITP
Conditions
Brief summary
Randomized, open-label, multicenter study to compare the efficacy and safety of combination of iguratimod and danazol versus danazol for the treatment of adults with steroid-resistant/ relapse immune thrombocytopenia (ITP).
Detailed description
The investigators are undertaking a parallel group, multicenter, randomized controlled trial of 100 adults with steroid-resistant/ relapse ITP in China. Patients were randomized to Iguratimod plus danazol and danazol monotherapy group. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study.
Interventions
DRUGIguratimod
Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.
DRUGDanazol
Oral danazol (200 mg twice daily) for 12 weeks.
Sponsors
Beijing Hospital
China-Japan Friendship Hospital
Beijing Friendship Hospital
The First Affiliated Hospital of Zhengzhou University
First Affiliated Hospital of Chongqing Medical University
Shanxi Bethune Hospital
Peking University People's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Primary immune thrombocytopenia (ITP) confirmed by excluding other supervened causes of thrombocytopenia; * Platelet count of less than 30×109/L at enrollment; * Patients who did not achieve a sustained response to treatment with full-dose corticosteroids for a minimum duration of 4 weeks or who relapsed during steroid-tapering or after its discontinuation; * 18 years older;
Exclusion criteria
* Secondary immune thrombocytopenia (e.g., patients with HIV, HCV, Helicobacter pylori infection or patients with systemic lupus erythematosus) * Congestive heart failure * Severe arrhythmia * Nursing or pregnant women * Aspartate aminotransferase and alanine transaminase levels ≥ 3× the upper limit of the normal threshold criteria * Creatinine or serum bilirubin levels each 1•5 times or more than the normal range * Active or previous malignancy * Unable to do blood routine test for the sake of time, distance, economic issues or other reasons.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sustained response | 6 months | The maintenance of platelet count ≥ 30 x 10\^9/L, at least 2-fold increase of the baseline count, the absence of bleeding, and no need for rescue medication at the 6-month follow-up. Interim analysis was scheduled at 50% through recruitment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete remission | 6 months | The number of participants (responders) with platelet count\>=100x10\^9/L (CR) and the absence of bleeding. |
| Partial remission | 6 months | The number of participants (responders) with platelet count \>=30x10\^9/L and at least a 2-fold increase in the baseline count (PR) without the administration of any other platelet increasing therapy. |
| Time to response | 6 months | Time to response was defined as the time from starting treatment to the time to achieve the response. |
| Duration of response | 6 months | Duration of response was measured from the achievement of response to the loss of response. |
| Incidence of treatment-emergent adverse events | 6 months | Adverse events were scaled according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
Countries
China
Contacts
Primary ContactXiao-Hui Zhang, MD
Backup ContactZhuo-Yu An, MD
Outcome results
None listed